Global Gabapentin Market 2021 to deliver Dynamic Progress

Gabapentin overview

Gabapentin is an anticonvulsant drug that is used to treat seizures, neuropathic pain, hot sweats, and restless legs syndrome. It can be used to treat partial seizures in epilepsy patients (Learn about Gabapentin Market Insights). It’s one of the first-line treatments for:

• Postherpetic neuralgia
• Diabetic neuropathy
• Central neuropathic pain

Gabapentin (Neurontin) was initially sold under the brand name Neurontin, and it has since been marketed under a number of different brand names since it became generic. Gralise, an extended-release gabapentin formulation for once-daily administration, was launched in 2011 for postherpetic neuralgia.

Gabapentin Market Progress

Gabapentin is mainly used for the treatment of epilepsy and neuropathic pain. Its most widely prescribed for a variety of off-label applications, including anxiety disorders, insomnia, and bipolar disorder therapy.

However, there are questions about the validity of the trials and evidence for some of these applications, especially in the case of its use as a mood stabilizer in bipolar disorder. It is estimated that the Gabapentin market will develop at a CAGR of 1.6 percent in terms of sales over the next five years, reaching US$ 1550 million in 2024 from US$ 1430 million in 2019. The global Gabapentin demand is forecast to rise at a CAGR of 1.8 percent from USD 1515.5 million in 2020 to USD 1686.7 million by 2026, up from USD 1515.5 million in 2020.

List of key Gabapentin vendors/manufacturers

Gabapentin is produced by a variety of various firms like:-

• Depomed
• Mylan
• Novartis
• Sun Pharmaceutical
• Intas
• Marksans Pharma
• Alkem
• Jiangsu Hengrui
• Pfizer
• TEVA
• Arbor Pharma
• Apotex
• Aurobindo Pharma
• Amneal
• Glenmark
• Jiangsu Enhua
• Sailike

The Geographical Analysis of Gabapentin Use

Market segments can be categorized based on geographical analysis and the study also provides a detailed analysis of the gabapentin market from 2019 to 2028. The actual and anticipated demand for them is in the following regions:-

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East
• Africa

Coronavirus Effect on the Gabapentin Drug Market

The epidemic has spread to almost every country around the world since the COVID-19 virus outbreak in December 2019, causing the World Health Organisation to declare it a public health emergency. The worldwide consequences of the coronavirus disease 2019 (COVID-19) are now being felt, and the Gabapentin Drug demand has greatly impacted. Flight cancellations, travel restrictions, and quarantines have all been affected by the COVID-19 epidemic, as have restaurants shutting and all indoor/outdoor activities being restricted; over forty countries have announced states of emergency; major supply chain delays; stock market volatility; declining corporate morale, and rising public panic.

Gabapentin Market Size and Scope in the World

The Gabapentin market is divided into four categories: business, area (country), kind, and application. Players, stakeholders, and other industry participants in the global Gabapentin market can achieve a competitive advantage by using the study as a valuable resource. For the period 2015-2026, the segmental review focuses on revenues, income, and forecast by area (country), type, and application.

Global Gabapentin Sales Market

Significant factors driving the global gabapentin distribution demand

• Gabapentin comes in both generic and brand-name varieties.
• It’s used to treat epilepsy, postherpetic neuralgia, and restless legs syndrome, among other things.

Global gabapentin sales demand restraining factors

• There is concern about side effects such as sleepiness, exhaustion, and vomiting.
• It can also lead to serious issues such as memory loss, weight gain, knee pain, and so on.

The global gabapentin distribution market is divided into four categories:

1. Technology
2. Care
3. Use
4. Geography

It includes pills and capsules depending on product form, nerve pain, restless legs syndrome, and epilepsy based on end-users.